(Q36532210)

14 August 2017

1 reference

title

Aneuploidy in bladder cancers: the utility of fluorescent in situ hybridization in clinical practice (English)

1 reference

14 August 2017

John L Phillips

1

1 reference

14 August 2017

Ingrid C Richardson

series ordinal

2

1 reference

14 August 2017

publication date

1 July 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

98

1 reference

14 August 2017

issue

1

1 reference

14 August 2017

page(s)

33-37

1 reference

Urine markers for bladder cancer surveillance: a systematic review

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

Molecular cytogenetic analysis of the bladder carcinoma cell line BK-10 by spectral karyotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

Intermediate-risk urothelial carcinoma: an unresolved problem?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

High-throughput tissue microarray analysis of erbB-2 gene amplification in urinary bladder cancer. A study of Bulgarian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

A Comparison of Routine Cytology and Fluorescence in situ Hybridization for the Detection of Malignant Bile Duct Strictures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2006.06189.X

10.1111/J.1464-410X.2006.06189.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference